| Project/Area Number |
16K19590
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
TEZUKA Kenta 国立感染症研究所, 血液・安全性研究部, 研究員 (10754533)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | HTLV-1 感染症 / 発症高リスク群 / Tax特異的CTL / iPS細胞 / HTLV-1 / 感染症 / 移植・再生医療 / 免疫学 / ウイルス |
|---|
| Outline of Final Research Achievements |
Toward achievement of the HTLV-1 prophylaxis and cure strategy, I assessed the potential for using induced pluripotent stem (iPS) cell technology for development of a new immunotherapy. The frequency of Tax-specific CTLs was quite low, and its phenotypes showed senescent, less survival, and dysfunctional behaviors in a portion of chronic HTLV-1 carriers with high proviral load (4% > PVL). Patient-derived HTLV-1-specific regenerated CTL therapy could be a promising strategy to prevent or treat HTLV-1-associated diseases among these carriers.
|
